| Authors: |
Madariaga A; Hospital Universitario 12 de Octubre. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Medical Oncology Department, Madrid, Spain., Veneziani A; Princess Margaret Hospital Cancer Centre, Medical Oncology and Hematology, Toronto, ON, Canada., Bookman M; Kaiser Permanente Northern California, San Francisco, CA, USA., Counsell N; University College London, Cancer Research United Kingdom & UCL Cancer Trials Centre, London, United Kingdom., Miller A; Roswell Park Comprehensive Cancer Center, Biostatistics & Bioinformatics, Clinical Trial Development Division, NRG Oncology, Buffalo, NY, USA., Andrews J; University of Sydney, NHMRC Clinical Trials Centre, Camperdown, NSW, Australia., Banerjee S; The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Gynaecology Unit, London, United Kingdom., Chavez-Blanco A; Gynaecologic Cancer InterGroup, Mexico City, Mexico., Cloven N; Sarah Cannon Research Institute, Texas Oncology, Fort Worth, TX, USA., Gaba F; Department of Gynaecological Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, United Kingdom., Kohn E; National Cancer Institute, Center for Cancer Research, Bethesda, MD, USA., Leary A; Gustave Roussy, Department of Medical Oncology, Villejuif, France., Lecuru F; APHP-Centre Université Paris Cité, Hôpital Européen Georges-Pompidou, Paris, France., Lee YC; University of Sydney, National Health and Medical Research Council Clinical Trials Centre, Sydney, NSW, Australia., Lee JY; Yonsei University College of Medicine, Department of Obstetrics and Gynecology, Seoul, South Korea., Liu Y; Memorial Sloan Kettering Cancer Center, Department of Medical Oncology, New York, NY, USA., Lindemann K; University of Oslo, Institute of Clinical Medicine, Faculty of Medicine, Oslo University Hospital, Department of Gynaecological Cancer, Oslo, Norway., Malik S; National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Bethesda, MD, USA., Marth C; Innsbruck Medical University, Department of Obstetrics and Gynecology, Innsbruck, Austria., Mileshkin L; Peter MacCallum Cancer Centre, Division of Cancer Medicine, Melbourne, VIC, Australia., Mukhopadhyay A; Chittaranjan National Cancer Institute, Kolkata Gynecological Oncology Trials and Translational Research Group, Kolkata, India., Nadeem A; Ovarian Cancer Canada, Patient Advocacy Group, Toronto, ON, Canada., Nout R; Leiden University Medical Center, Department of Radiation Oncology, Leiden, The Netherlands., Pérez-Fidalgo JA; INCLIVA Biomedical Research Institute, University Hospital of Valencia, Medical Oncology Department, Valencia, Spain., Plante M; Laval University, L'Hôtel-Dieu de Québec, CHU de Québec, Gynecologic Oncology Division, Quebec City, QC, Canada., Sundar S; University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom., Tone A; Ovarian Cancer Canada, Patient Advocacy Group, Toronto, ON, Canada., Oza AM; Princess Margaret Hospital Cancer Centre, Medical Oncology and Hematology, Toronto, ON, Canada., Glasspool R; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. Electronic address: ros.glasspool@ggc.scot.nhs.uk., MacKay H; Sunnybrook Health Sciences Centre, Medical Oncology & Hematology, Toronto, ON, Canada. Electronic address: helen.mackay@sunnybrook.ca. |
